ArticleeLife2014
HIV-1 DNA predicts disease progression and post-treatment virological control.
Article in eLife, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03198325 (Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia), which is not on this map. Cited by 195 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia (APACHE Study)
Who cites it
195 citing papers in PubMed, 5 syntheses or guidelines pooled it, 305 citations in OpenAlex.
- Reservoir differences across HIV-1 subtypes: a systematic review to guide cure research.Frontiers in immunology · 2026Pooled it
- Association between baseline HIV-1 DNA levels and clinical outcomes in people living with HIV: a meta-analysis of cohort studies.Emerging microbes & infections · 2025Pooled it
- Adjuvant roles of interleukin-7 in enhancing T cell recovery during antiretroviral therapy for individuals with HIV: a systematic review and meta-analysis.Annals of medicine · 2025Pooled it
- Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.Nature communications · 2025Pooled it
- Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.AIDS reviews · 2020Pooled it
- Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults.BMC infectious diseases · 2022Trial
- Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.AIDS research and therapy · 2022Trial
- Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.Scientific reports · 2022Trial
- Therapeutic prediction of HIV-1 DNA decay: a multicenter longitudinal cohort study.BMC infectious diseases · 2021Trial
- Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts.EBioMedicine · 2020Trial
- Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.JCI insight · 2020Trial
- HIV-1 CRF01_AE subtype and HIV-1 DNA level among patients with chronic HIV-1 infection: a correlation study.BMC infectious diseases · 2020Trial
- Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men.AIDS (London, England) · 2019Trial
- The effects of antiretroviral therapy initiation time on HIV reservoir size in Chinese chronically HIV infected patients: a prospective, multi-site cohort study.BMC infectious diseases · 2019Trial
- Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.AIDS (London, England) · 2019Trial
- Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects.Journal of the International AIDS Society · 2017Trial
- Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.AIDS (London, England) · 2017Trial
- Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.PloS one · 2017Trial
- Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.The lancet. HIV · 2016Trial
135 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 9 institutions in 5 countries.
Funding
Abstract
In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.